Our CEO, Dr James Garner recently conducted an interview with FNN which focused on the recent interim data from Kazia’s ongoing phase II trial of paxalisib in glioblastoma.
Kazia CEO, Dr James Garner discusses the recent positive interim data from the ongoing phase II trial of paxalisib in glioblastoma, COVID-19 and the company's recent capital raising.